- Ponalrestat
-
- $39.00 / 10mg
-
2026-02-02
- CAS:72702-95-5
- Min. Order:
- Purity: 98.05%
- Supply Ability: 10g
|
| Product Name: | STATIL | | Synonyms: | STATIL;[3-(4-BROMO-2-FLUOROBENZYL)-4-OXO-3H-PHTHALAZIN-1-YL]ACETIC ACID;Ponalrestat;3-(4-BROMO-2-FLUOROBENZYL)-4-OXO-3H-PHTHALAZIN-1-YL]ACETIC ACID (STATIL);3-[(4-Bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid;ICI-128436;ICI-plc;MK-538 | | CAS: | 72702-95-5 | | MF: | C17H12BrFN2O3 | | MW: | 391.19 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 72702-95-5.mol |  |
| | STATIL Chemical Properties |
| Melting point | 184-186℃ (DEC.) | | density | 1.60 | | storage temp. | Store at RT | | solubility | DMF: 2 mg/mL; DMSO: 2 mg/mL; Ethanol: 2 mg/mL; PBS (pH 7.2): 0.2 mg/mL | | form | A crystalline solid | | color | White to off-white | | InChI | InChI=1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23) | | InChIKey | LKBFFDOJUKLQNY-UHFFFAOYSA-N | | SMILES | C12C=CC=CC=1C(=O)N(CC1=CC=C(Br)C=C1F)N=C2CC(=O)O |
| Risk Statements | 36/37/38 | | Safety Statements | 26-36/37/39 | | WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | STATIL Usage And Synthesis |
| Description | Statil is an aldose reductase inhibitor that blocks the conversion of glucose to sorbitol. It demonstrates selectivity for aldose reductase 2 over aldose reductase 1 with Ki values of 7.7 nM and 60 μM, respectively. Statil has been shown to prevent diabetes-induced alterations of the cardiovascular system in 14-day streptozotocin-diabetic rats. Aldose reductase inhibition by statil has also been used to impair the synthesis of prostaglandin F2α by human cultured preadipocytes. | | Uses | Inhibitor (aldose reductase). | | Uses | Statil is a knon aldose reductase inhibitor which blocks the conversion of glucose to sorbitol. In addition it suppresses cell cancer growth | | Definition | ChEBI: 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid is a member of phthalazines. | | Biological Activity | Potent aldose reductase inhibitor. | | in vivo | Ponalrestat (ICI 128436; 10, 50 mg/kg; orally; daily; 8 weeks) reduces sorbitol accumulation indicating efficacy of aldose reductase inhibition[3].
| Animal Model: | Adult female Sprague-Dawley rats[3] | | Dosage: | 10, 50 mg/kg | | Administration: | Orally; daily; 8 weeks | | Result: | Reduced sorbitol accumulation.
|
| | References | [1] WALTER H.J. WARD . Ponalrestat: A potent and specific inhibitor of aldose reductase[J]. Biochemical pharmacology, 1990, 39 2: Pages 337-346. DOI: 10.1016/0006-2952(90)90033-h
[2] DONNA J. OTTER Russell C W. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats[J]. British Journal of Pharmacology, 1994, 113 2: 576-580. DOI: 10.1111/j.1476-5381.1994.tb17028.x
[3] ANDRéANNE MICHAUD. Prostaglandin (PG) F2 alpha synthesis in human subcutaneous and omental adipose tissue: modulation by inflammatory cytokines and role of the human aldose reductase AKR1B1.[J]. PLoS ONE, 2014: e90861. DOI: 10.1371/journal.pone.0090861 |
| | STATIL Preparation Products And Raw materials |
|